Taysha Gene Therapies Inc (NAS:TSHA)
$ 2.055 -0.095 (-4.42%) Market Cap: 413.83 Mil Enterprise Value: 370.70 Mil PE Ratio: 0 PB Ratio: 7.09 GF Score: 31/100

Q4 2022 Taysha Gene Therapies Inc Earnings Call Transcript

Mar 28, 2023 / 08:30PM GMT
Release Date Price: $0.652 (-6.19%)
Operator

Greetings, and welcome to the Taysha Gene Therapies Fourth Quarter and Full Year 2022 Earnings Call. (Operator Instructions)

As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Hayleigh Collins, Director and Head of Corporate Communications. Thank you, Ms. Collins, you may begin.

Hayleigh Collins

Thank you. Good afternoon, and welcome to Taysha's Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Conference Call. I'm Hayleigh Collins, Taysha's recently appointed Director and Head of Corporate Communications. I'll also be overseeing Investor Relations activities with Corporate Communications experience in rare diseases, having previously served in a similar role at Jaguar Gene Therapy. I'm excited to join Taysha at this pivotal time and look forward to working with the team to help bring potentially life-changing therapies to patients with rare diseases with high unmet medical needs.

Earlier today, Taysha issued a press release announcing financial results for the fourth quarter and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot